Figure 1From: Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerMean AS1402 serum concentration-versus-time profiles (± SD) after i.v. administration to patients at doses of 1 mg/kg (circle), 3 mg/kg (triangle), 9 mg/kg (square), or 16 mg/kg (diamond). An antibody concentration of 10 μg/ml was sufficient to elicit ADCC to kill breast cancer cells in vitro.Back to article page